At a data cut-off of 37.3 months, EFS improved to 3.4 months for crenolanib, compared with 0.0 months for placebo.
TipRanks on MSN
Aptose’s tuspetinib shows promising results in AML treatment
The latest update is out from Aptose Biosciences ( (TSE:APS) ).
TipRanks on MSN
PureTech’s Gallop Oncology reports positive Phase 1b trial results for LYT-200 in AML
An update from PureTech Health ( ($GB:PRTC) ) is now available. Gallop Oncology, a PureTech Health entity, announced promising results from a ...
Detailed price information for Aptose Biosciences Inc (APTOF) from The Globe and Mail including charting and trades.
AML fights financial crime by tracking and reporting suspicious crypto transactions. Know Your Customer (KYC) checks are a cornerstone of AML, verifying user identities. The Travel Rule mandates ...
Kura Oncology's FDA-approved Komzifti and strong financials offer growth potential in the evolving AML market. Learn more ...
Kura Oncology remains a Strong Buy, driven by Ziftomenib's differentiated safety profile and significant AML market potential. Click here to read my analysis.
What Is Acute Myeloid Leukemia? Acute myeloid leukemia (AML) is a type of blood cancer that starts in your bone marrow, which is the soft inner part of your bones where all your blood cells are made.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback